Biden Renews Call for Lowering Insulin Costs and Letting Medicare Negotiate Drug Prices

President Joe Biden delivering State of the Union speech
President Biden urged Congress in his State of the Union message to cap monthly cost sharing for insulin at $35 and let Medicare negotiate what it pays for prescription drugs.

President Biden urged Congress in his State of the Union message Tuesday night to cap monthly cost sharing for insulin at $35 and let Medicare negotiate what it pays for prescription drugs.

Biden said cutting the cost of prescription drugs

Read More »

Congressional Democrats Confront PhRMA About Brand Drug Price Hikes

Sen. Elizabeth Warren speaking at an event
Sen. Elizabeth Warren (D-Mass.) was one of the organizers of a congressional Democratic letter to PhRMA inquiring about "rapid price hikes affecting the vast majority of popular brand name drugs.”

Thirteen congressional Democrats—eight senators and five representatives—asked Pharmaceutical Research and Manufacturers of America (PhRMA) to respond by March 8 to questions about “rapid price hikes affecting the vast majority of popular brand name drugs.”

Sens. Elizabeth Warren (Mass.) and Amy

Read More »

AstraZeneca and Feds Disagree Over Next Steps in 340B Contract Pharmacy Case

AstraZeneca building-mounted sign
AstraZeneca and the federal government disagree over what a federal district judge should do next in the drug company's 340B contract pharmacy lawsuit.

The federal government indicated in a court filing last week that it will appeal the court’s decision striking down and vacating the government’s letter telling drug company AstraZeneca its conditions on 340B pricing when covered entities use contract pharmacy were

Read More »

340B Stakeholders Congratulate Egwim on Being Named OPA Director

Lt. Cmdr. Emeka Egwim headshot
U.S. Public Health Service Lieutenant Commander Emeka Egwim left his position as director of OPA at HRSA 21 months after he started.

340B provider and drug industry stakeholders joined yesterday in congratulating U.S. Public Health Service Lt. Cmdr. Emeka Egwim on his selection as Director of the U.S. Office of Pharmacy Affairs, the federal agency that runs the 340B drug pricing program. 

Read More »

Biden to Address Drug Pricing in Speech Tonight Amid Signs of Shift in Congressional Dems’ Strategy

Joe Biden with microphone on stage
President Biden will talk about lowering prescription drug costs in his State of the Union message tonight, the White House said. | Gage Skidmore / Flickr

A Democratic push in Congress to cap insulin costs for patients is gaining momentum. It may be a sign that some in the party are giving up on trying to pass comprehensive drug pricing legislation and focusing now on trying

Read More »

Breaking News

HRSA Picks Federal HIV/AIDS Policy Specialist Emeka Egwim To Be its Next 340B Program Director

Lt. Cmdr. Emeka Edwim headshot
PHS Lt. Cmdr. Emeka Edwim is the new Director of HRSA's Office of Pharmacy Affairs, the HRSA unit that runs the 340B drug pricing program.

Emeka Egwim, a federal government HIV/AIDS policy specialist who also has served in the Medicaid Drug Rebate Program, is the new head of the federal 340B Drug Pricing Program.

In a letter this morning to its staff, the U.S. Health

Read More »

Despite Expected Jan. Publication Date, White House Review of New 340B ADR Proposed Rule Is Approaching 100-Day Mark

HRSA's proposed replacement for its year-old 340B administrative dispute resolution process has been under White House review for almost 100 days.

The U.S. Health Resources and Services Administration’s (HRSA) proposed replacement for its year-old 340B administrative dispute resolution (ADR) process has been under White House review for almost 100 days—nearly a month longer that the anticipated release date announced in November.

Read More »

Hospitals Say the Three Confirmed to Have Left 340B Due to Fallout from COVID Are the Tip of the Iceberg

ProMedica Memorial Hospital in Ohio had to leave the 340B program last year when it lost eligibility due to fallout from COVID-19.

The U.S. Health Resources and Services Administration’s (HRSA) recent statement that only three hospitals so far have said on a federal form that they lost their 340B eligibility due to fallout from COVID-19 does not reflect the problem’s much bigger

Read More »

Rural Providers Ask Becerra for Action on 340B Contract Pharmacy and on Hospitals at Risk of Losing 340B Eligibility

The NRHA wants HHS to act against drug companies that deny 340B pricing when covered entities use contract pharmacies and ensure that rural hospitals do not lose their 340B eligibility due to factors related to COVID-19.

The National Rural Health Association (NRHA) asked U.S. Health and Human Services (HHS) Secretary Xavier Becerra this week to act against drug manufacturers that deny 340B pricing when covered entities use contract pharmacies.

NRHA CEO Alan Morgan also urged Becerra

Read More »

New JAMA Study Casts Doubt on CMS Reason for Cutting Hospitals’ Medicare Part B Payments for 340B Drugs

screenshot of JAMA Open access article about 340B
New research “raises doubt” about a major CMS reason for slashing hospitals’ Medicare Part B reimbursement for drugs purchased through the 340B program by almost one-third.

New research published in JAMA Network Open “raises doubt” about a major U.S. Centers for Medicare & Medicaid Services (CMS) justification for slashing hospitals’ Medicare Part B reimbursement for drugs purchased through the 340B program by almost one-third, the study’s

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live